INmune BioINMB -4.59%52 Gross Margin % is 0.00% as of Mar. 2026. GuruFocus rates INMB with a GF Score™ of 52/100 and a GF Value™ of $1.84 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 738 Biotechnology companies, INmune Bio ranks worse than 135501.22% on this metric.
The historical rank and industry rank for INmune Bio's Gross Margin % or its related term are showing as below:
INMB's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.94 * Ranked among companies with meaningful Gross Margin % only.
INmune Bio had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for INmune Bio was 0.00% per year.
INmune Bio (NAS:INMB) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
INmune Bio had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
INmune Bio Gross Margin % Related Terms
INmune Bio Gross Margin % Historical Data
* Premium members only.
The historical data trend for INmune Bio's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INMB vs GRDX, VERU, ABVC: Gross Margin % Comparison
For the Biotechnology subindustry, INmune Bio's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
INmune Bio Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, INmune Bio's Gross Margin % distribution charts can be found below:
* The bar in red indicates where INmune Bio's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
INmune Bio (INMB) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on INmune Bio and its competitors. According to the industry distribution chart, INmune Bio ranks #999999 out of 738 companies in the Biotechnology industry.
Is INmune Bio's Gross Margin % too high?
INmune Bio's current Gross Margin % is 0.00%. Based on the distribution chart, INmune Bio ranks #999999 out of 738 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, INmune Bio has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's Gross Margin % compare to GRDX and VERU?
According to the Biotechnology industry distribution chart, INmune Bio ranks #999999 out of 738 companies for Gross Margin %. This places INmune Bio in the lower half of its industry. The industry median Gross Margin % is 60.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on INmune Bio and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. INmune Bio's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.84, compared to a current price of $1.35 — trading 26.6% below its estimated fair value. The current Gross Margin % is 0.00%. INmune Bio's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For INmune Bio (INMB), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is INmune Bio (INMB) Overvalued in 2026?
Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued.
The current stock price of $1.35 is trading 26.6% below its estimated GF Value™ of $1.84.
GuruFocus considers INmune Bio to be Modestly Undervalued.
Key valuation signals for INMB:
Gross Margin %: 0.00%
GF Value™: $1.84 vs. price of $1.35 (26.6% below fair value)
No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
52GF Score
Get the complete analysis for INMB
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INMB has been successfully added to your 
